For research use only. Not for therapeutic Use.
GalNAc unconjugated/naked Inclisiran（Cat No.:I041223）is an RNA interference (RNAi) therapeutic designed to reduce low-density lipoprotein cholesterol (LDL-C) levels. Inclisiran targets the PCSK9 gene, inhibiting its expression and enhancing the liver’s ability to clear LDL-C from the bloodstream. The GalNAc (N-acetylgalactosamine) moiety, when conjugated, facilitates targeted delivery to liver cells, but in its unconjugated/naked form, Inclisiran lacks this targeting feature. Research is focused on assessing the compound’s efficacy and safety profile, with potential applications in the treatment of hypercholesterolemia and cardiovascular diseases, particularly in patients with elevated LDL-C levels.
| Purity | ≥95% |
